Dataset Information
Evaluation of eltrombopag in patients with aplastic anemia in real-world experience.
Ontology highlight
ABSTRACT: Background
Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown.Methods
We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018.Results
Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil-to-lymphocyte ratio and platelet counts were significantly different between the responders and non-responders.Conclusion
Eltrombopag is a promising agent for treating patients with any degree of AA.
SUBMITTER: Konishi A
PROVIDER: S-EPMC6416522 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Publications
Evaluation of eltrombopag in patients with aplastic anemia in real-world experience.
Leukemia research reports 20190305
<h4>Background</h4>Although eltrombopag has recently been approved for treating AA, the effects of its clinical use remain unknown.<h4>Methods</h4>We retrospectively analyzed 11 patients with AA, who had been treated with eltrombopag from August 2017 to May 2018.<h4>Results</h4>Overall response rate was 55%. There was tri-lineage recovery in four patients and platelet recovery in two. The reactive time was within 8 weeks after treatment initiation. Stage at the initial assessment, the neutrophil ...[more]